PURPOSE: We determined if urethral preservation and @entity1494 replacement in @entity1 with @entity1606 within the prostatic urethra or prostate placed these @entity1 at risk for urethral recurrence or @entity204 . MATERIALS AND METHODS: The clinical course of all @entity1 undergoing urethral preservation and @entity1494 replacement was reviewed. The urethra was sacrificed only if the distal prostatic urethral margin was positive for @entity1606 . The pathological T stage and the grade of the primary @entity5 , local recurrence, site of recurrence (urethral, pelvic, distant) and @entity204 were documented. RESULTS: Of 81 @entity1 70 were evaluable (June 1996) with a mean followup of 35 months. Of the 70 @entity1 48 were alive without evidence of disease for a mean of 38 months (range 8 to 107) and 5 died without evidence of disease. Eight of these 53 @entity1 (15%) had prostatic involvement ( @entity189 in situ in 6, @entity3821 in 1 and @entity1606 in 1). Of the 70 @entity1 17 had disease recurrence (13 died of disease and 4 are alive, 1 of whom had urethral recurrence without @entity263 ). Of the 17 @entity1 (35%) 6 had @entity1606 prostatic involvement ( @entity189 in situ in 4 and stromal invasion in 2), and 5 of these 6 died, none with or of urethral recurrence but of the primary bladder pathology. Of these 5 @entity1 1 had @entity1606 of the prostate and experienced a bulbar urethra recurrence at 1 month and a pelvic recurrence at 3 months, and died at 5 months. Death was not secondary to the urethral recurrence. Thus, of the 14 @entity1 who had @entity263 , only 1 had urethral recurrence (7%), and this recurrence did not present as the cause of @entity204 . CONCLUSIONS: The guidelines for urethral resection can be relaxed, increasing the opportunities for orthotopic reconstruction, without placing the @entity1 at increased risk for @entity1606 .

Does prostate @entity1606 preclude XXXX reconstruction after radical cystoprostatectomy for bladder cancer?

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3821 :: ('MESH:D002285', 'Disease') :: ['intraductal carcinoma'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostatic transitional cell carcinoma', 'initial prostatic transitional cell carcinoma'] @entity1494 :: ('MESH:D001745', 'Disease') :: ['orthotopic bladder'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancy'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma'] @entity1606 :: ('MESH:D002295', 'Disease') :: ['death of transitional cell carcinoma', 'transitional cell carcinoma', 'stromal invasive transitional cell carcinoma'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity1494 :: (MESH:D001745,Disease) :: ['orthotopic bladder']
